When CMS finalized coverage for cardiac ablations performed in ASCs, experts from HRS and ACC published recommendations for performing those procedures safely and effectively. One of the cardiologists behind that guidance shared some important takeaways with Cardiovascular Business.
When CMS finalized coverage for cardiac ablations performed in ASCs, experts from HRS and ACC published recommendations for performing those procedures safely and effectively. One of the cardiologists behind that guidance shared some important takeaways with Cardiovascular Business.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](https://cardiovascularbusiness.com/sites/default/files/styles/media_thumbnail/public/2024-09/istock-1209664264.jpg?itok=d9hdApI9)
